Navigation Links


Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Computer Electronics, Biotechnology, Clinical Trials & Medical Discoveries Click to view news release full screen  



Combination of Toraymyxin™ and EAA™ represents first theranostic trial in sepsis

TORONTO, Oct. 19 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX:SDI), a Phase III company seeking FDA approval for its lead theranostics product for the treatment severe sepsis and septic shock, today announced initiation of its U.S. pivotal trial of Toraymyxin™, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream, for patients with severe sepsis. The Cooper Health System, in Camden, New Jersey, which also acts as the coordinating centre for the EUPHRATES trial, has been screening patients using the FDA approved protocol for inclusion and exclusion criteria. After determining the suitability of the protocol, patients have now been enrolled in the trial.

The EUPHRATES (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock) trial is a randomized, double-blinded control trial of standard of care versus standard of care and Toraymyxin™ directed by Spectral's Endotoxin Activity Assay (EAA™), an FDA cleared assay for use in sepsis. This is the first theranostics trial, a combination therapeutic and diagnostic, in the area of sepsis.

"The initiation of our EUPHRATES trial is a major milestone for the Company. This is a step closer to providing U.S. patients the opportunity to access this unique therapeutic device," said Dr. Paul Walker, President and CEO of Spectral. "In part due to the few therapeutic options available to treat the more than 250,000 patients diagnosed with severe sepsis in the U.S. each year, this disease remains a leading cause of mortality. Toraymyxin™ has been used safely on more than 70,000 patients worldwide and, when guided by our EAA™ diagnostic, has the potential to address this large unmet medical need. We are now qualifying additional sites and, following the upcoming investigators meeting, anticipate that all 15 sites should be active within the next three months."

The EUPHRATES trial is expected to enroll approximately 360 patients at 15 sites throughout the U.S. and will have a primary end point of 28 day mortality. About Spectral Diagnostics Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment for severe sepsis and septic shock. Toraymyxin™ is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the detection of endotoxin. Spectral's EUPHRATES trial is the world's first theranostics trial in the area of sepsis.

Toraymyxin™ has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively in more than 70,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for Toraymyxin™. More than 250,000 patients are diagnosed with severe sepsis and septic shock in the U.S. each year, representing a greater than $1 billion market opportunity for Spectral.

Spectral is listed on the Toronto Stock Exchange under the symbol SDI. Forward-looking statement Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws.  Implicit in this information, particularly in respect of our future operating results and economic performance and anticipated events or results, are assumptions based on beliefs of our senior management as well as information currently available to it.  These assumptions, although considered reasonable by us at the time of preparation, may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, our ability to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.  For more exhaustive information on these risks and uncertainties you should refer to our most recently filed annual information form which is available at  Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

SOURCE Spectral Diagnostics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Spectral to bring anti-sepsis therapy to the U.S. market
2. Spectral announces third quarter 2008 results
3. Surface plasmon resonances of metal nanoparticles in array can have narrower spectral widths
4. Spectral signs exclusive license agreement to bring sepsis therapeutic to the U.S. market
5. Spectral announces 2008 financial results
6. Spectral announces presentations at the 29TH International Symposium on Intensive Care and Emergency Medicine focusing on the role of endotoxin
7. Spectral announces first quarter 2009 results
8. Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial
9. Spectral announces second quarter 2009 results
10. Spectral appoints new board member
11. First Spaceborne Hyperspectral Imager Will Use QImaging Rolera-MGi EMCCD Camera
Post Your Comments:
(Date:10/8/2015)... -- Celemics, a global pioneer of personalized medicine genetics, ... with the establishment of Celemics America, Inc. ... , has secured itself in the global market ... preparation for DNA sequencing and genetic testing.  Next Generation ... testing more accurately, quickly, and cost effectively than traditional ...
(Date:10/8/2015)... 2015 The 2015 Nobel Prize in Chemistry ... at Dallas. Aziz Sancar , who earned his PhD ... in 1977, is one of three scientists who received the ... repair damaged DNA on a molecular level.  --> Aziz ... from UT Dallas in 1977, is one ...
(Date:10/8/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... development of autologous cell therapies, today announced its schedule of ... in the month of October: Stem Cell ... will be presenting at the annual Partnering Forum, part ... be held October 7-9 in La Jolla, ...
(Date:10/8/2015)... ... 2015 , ... Talon Innovations, a provider of Precision Machined Products ... it is one of three finalists for the Minnesota Business magazine’s Manufacturing Award in ... Talon Innovations was recognized as a nominee for this competitive award. , The ...
Breaking Biology Technology:
... DUBLIN , June 17, 2010 An ... hour blood,pressure is more accurate and consistent than a leading group of,international ... ... the study,analysed the interpretation of numerous blood pressure readings taken over a,24-hour ...
... becoming increasingly flatter - some have even become almost as ... dimensions, much to the delight of home cinema fans. Cellphones ... All of these developments owe their thanks to miniature light-emitting ... multitude of devices. However, LED technology does have a ...
... ... an occlusion-induced IR injury model enabling the ability to study the functional relevance of ... which the drug promotes myocardial protection. , ... (PRWEB) June 16, 2010 -- MD Biosciences , a ...
Cached Biology Technology:
(Date:9/28/2015)... September 28, 2015 According to ... & Software), Product (Scanner & Others), Application (Access Control ... & Others) & Geography Global - Forecast to 2020", published ... reach USD 3627.90 Million by 2020, at a CAGR ... Browse 65 market data T ables and ...
(Date:9/26/2015)...  Results of a TactioRPM pilot project in ... the Stanford Medicine X Conference. In a presentation ... Health Devices and Pharmacogenomics", Roger Simard , ... how senior patients equipped with connected health devices ... the TactioRPM remote patient monitoring platform were empowered ...
(Date:9/24/2015)... , September 24, 2015 ... september 2015 Kerv ( ... finanstjänster, lanserar idag världens första kontaktlösa betalningsring ... in 77 000 GBP för massproduktion via ... ) , Kerv-bärare kan ...
Breaking Biology News(10 mins):
... part in the National Science Foundation,s (NSF) Faculty ... additional distinction as winners of Presidential Early Career ... 2006 competition. The PECASE program recognizes outstanding ... show exceptional potential for leadership at the frontiers ...
... wildfires can contribute as much as vehicles to carbon ... highly variable. New research published in the online open ... and suggests fires will complicate emissions monitoring and modelling ... Atmospheric Research and Jason Neff of the University of ...
... State University have designed a revolutionary laser technique which ... damaging human cells and may also help reduce the ... The research, published on Thursday November 1 in ... discusses how pulses from an infrared laser can be ...
Cached Biology News: